• Online Features  This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

Jerry L. Bauman, PharmD; Robert J. DiDomenico, PharmD; Marlos Viana, PhD; Melissa Fitch, PharmD

Arch Intern Med. 2006;166:2539-2545.

Background  The therapeutic range for digoxin in heart failure has recently changed to become lower and narrower, and the new range is associated with improved mortality. However, dosing methods have not been modified to reflect this change. In this study, we sought to develop a new method to determine the initial dose of digoxin in patients with heart failure.

Methods  Over a 6-month period, medical records were screened and reviewed for hospitalized adult patients who had a steady state digoxin concentration. A multiple linear regression was estimated relating digoxin concentration, digoxin dose, creatinine clearance, and ideal body weight to generate an equation relating the dose of digoxin with these variables and a specific target digoxin concentration of 0.7 ng/mL (0.9 nmol/L). This new method was then compared with 2 existing methods.

Results  Included in the study were 54 patients (mean [SD] age, 68 [15] years, with a mean (SD) creatinine clearance of 50 (25) mL/min (0.8 [0.4] mL/s) and mean (SD) ideal body weight of 62 (11) kg. Our proposed method and the Jusko and Koup method were more accurate than the Jelliffe method in predicting digoxin concentration. Root mean square errors were as follows: for the Jelliffe method (using ideal body weight), 0.810; for the Koup and Jusko method (with heart failure), 0.401; our proposed method, 0.375. The proposed method was then used to create a dosing nomogram.

Conclusions  Because the new therapeutic window of digoxin is associated with improved outcomes, more intensive dosage refinement should be considered. To this end, we offer new dosing recommendations and a nomogram for determining the initial dose of digoxin in patients with heart failure.

Author Affiliations: Departments of Pharmacy Practice (Drs Bauman, DiDomenico, Viana, and Fitch) and Medicine, Section of Cardiology (Drs Bauman and DiDomenico), and Eye and Ear Infirmary (Dr Viana), University of Illinois at Chicago, Chicago.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Digoxin in chronic heart failure: possibility of a second chance?
Vaz Perez et al.
QJM 2011;104:369-371.
FULL TEXT  

Individual dosage of digoxin in patients with heart failure
Muzzarelli et al.
QJM 2011;104:309-317.
ABSTRACT | FULL TEXT  

A New Proposed Nomogram for Digoxin Dosing in HF
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT